The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD
Abstract
OBJECTIVES: Treatment investigations with methylphenidate in adults with ADHD focus preferentially on the classical psychopathology: inattention, hyperactivity and impulsivity. ADHD-associated emotional symptoms, which are frequently present at least in ADHD subpopulations, were studied rarely. The vast majority of the placebo-controlled trials had observation periods between 4 and 8 weeks. To assess the medium- to long-term effects of extended release methylphenidate (MPH-ER) on emotional symptoms and other psychopathology frequently seen in ADHD patients, we conducted a large-scale, multicenter treatment study. METHODS: We performed a randomised, 24-week, double-blind, placebo-controlled study in adults with ADHD. The diagnosis was made on the basis of the DSM-IV criteria, which were confirmed by clinical history and a structured psychopathological interview and the use of rating instruments. 363 patients were randomized to MPH-ER or placebo at a ratio of 2:1. The duration of the titration period was 5 weeks followed by a maintainance phase of 19 weeks. The efficacy measures were the observer rated 10-item Emotional Dysregulation Scale (EDS) derived from the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) and a self-report, six-item Emotional Lability Scale (ELS) extracted from the long version of the Conners Adult ADHD Self Report Scale (CAARS:S:L). In addition we used the SCL-90-R for the assessment of ADHD associated and comorbid psychopathology. RESULTS: MPH-ER was statistically superior to placebo in reducing emotional symptoms as assessed by the EDS and the ELS. Obsessive-compulsive symptoms and those of problems with self-concept declined until the end of the observation period. The decline was more pronounced in MPH-ER treated individuals. The effects remained robust during the entire maintenance period until week 24. Symptoms of anxiety, depression, anger and hostility, phobia, paranoid ideations and psychoticism were not improved. CONCLUSIONS: MPH-ER appears to be an efficacious treatment for emotional symptoms with ADHD. Also obsessive-compulsive symptoms and problems with self-concept were affected positively.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Psychiatric and behavioral comorbidities, such as depression, anxiety disorder, bipolar disorder, substance use, and personality disorders, often co-occur with ADHD and result in increased difficulties for appropriate diagnoses and treatments (Barkley and Brown, 2008; Rosler et al., 2010; Mao and Findling, 2014; Katzman et al., 2017).”
From A Review of Heterogeneity in Attention Deficit/Hyperactivity Disorder (ADHD) (2019) · cites this paper as Rosler et al., 2010
In the citing paper
“The effect size ranged from 0.28 to 0.4, which is lower than stimulants’ effect size on diagnostic ADHD symptoms (meta-analyses suggest a range of 0.6–0.8 [36, 37]), but it is still clinically significant.”
From Using Stimulants to Treat ADHD-Related Emotional Lability (2014) · cites this paper as [34]
In the citing paper
“Following 24 weeks of treatment with extended release methylphenidate (MPH-ER), there was a significant reduction in emotional lability, as assessed by the emotional dysregulation items on the Wender-Reimherr Adult ADHD Scale [35].”
From Using Stimulants to Treat ADHD-Related Emotional Lability (2014) · cites this paper as [34]
Citations
Cites
(1998) · Cited by 2,026
Biederman, J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.816 · Cited by 1,498
Mannuzza, S. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820190067007 · Cited by 1,368
Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder
Fayyad, J., De Graaf, R., Kessler, R., Alonso, J., Angermeyer, M., Demyttenaere, K., De Girolamo, G., Haro, J. M., Karam, E. G., Lara, C., et al. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.034389 · Cited by 1,321
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790
Wïttchen, H., Wunderlich, U., Gruschwitz, S., & Zaudig, M. (1997) · Max Planck Institute for Plasma Physics · Cited by 769
WEISS, G., HECHTMAN, L., MILROY, T., & PERLMAN, T. (1985) · Journal of the American Academy of Child Psychiatry · doi:10.1016/s0002-7138(09)60450-7 · Cited by 753
ATTENTION-DEFICIT HYPERACTIVITY DISORDER IN ADULTS
Wender, P. H. (1998) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70039-3 · Cited by 728
Prevalence, Clinical Correlates, and Longitudinal Course of Severe Mood Dysregulation in Children
Brotman, M. A., Schmajuk, M., Rich, B. A., Dickstein, D. P., Guyer, A. E., Costello, E. J., EGGER, H. L., Angold, A. C., Pine, D. S., & Leibenluft, E. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.042 · Cited by 491
Research works printed but not linked: 2
- Biederman J, 2004, J Clin Psychiatry, 65, 3
- Weiss MD, 2004, J Clin Psychiatry, 65, 27
Cited by
Sorted by citations
Emotion Dysregulation in Attention Deficit Hyperactivity Disorder
Shaw, P., Stringaris, A., Nigg, J., & Leibenluft, E. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070966 · Cited by 1,232
Adult ADHD and comorbid disorders: clinical implications of a dimensional approach
Katzman, M. A., Bilkey, T. S., Chokka, P. R., Fallu, A., & Klassen, L. J. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1463-3 · Cited by 732
A Review of Heterogeneity in Attention Deficit/Hyperactivity Disorder (ADHD)
Luo, Y., Weibman, D., Halperin, J. M., & Li, X. (2019) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2019.00042 · Cited by 394
Faraone, S. V., Rostain, A. L., Blader, J., Busch, B., Childress, A. C., Connor, D. F., & Newcorn, J. H. (2019) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12899 · Cited by 400
Maternal emotion and cognitive control capacities and parenting: A conceptual framework
Crandall, A., Deater-Deckard, K. D., & Riley, A. W. (2015) · Developmental Review · doi:10.1016/j.dr.2015.01.004 · Cited by 417
Metadata
- Authors
- Rösler, M., Retz, W., Fischer, R., Ose, C., Alm, B., Deckert, J., Philipsen, A., Herpertz, S., & Ammer, R.
- Affiliations
- Universitätsklinikum des Saarlandes (DE)
- Medice (Germany) (DE)
- Institut für Medizinische Informatik, Biometrie und Epidemiologie (DE)
- Central Institute of Mental Health (DE)
- University of Würzburg (DE)
- University of Freiburg (DE)
- University of Rostock (DE)
- Corresponding author
- Rösler, Michael
- ORCID
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2010-03-30
- Volume
- 11
- Issue
- 5
- Pages
- 709-718
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W1985528539
- Cited by
- 131
- References
- 43
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 1 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 8 · 2019: 7 · 2018: 6 · 2017: 11 · 2016: 13 · 2015: 11 · 2014: 20 · 2013: 7 · 2012: 9
- FWCI
- 5.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The World Journal of Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- adult ADHD, extended-release methylphenidate, emotional symptoms, emotional dysregulation, emotional lability, obsessive-compulsive symptoms, self-concept, long-term treatment efficacy, comorbid psychopathology
- MeSH terms
- Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Delayed-Action Preparations, Double-Blind Method, Emotions, Female, Follow-Up Studies, Humans, Long-Term Care, Male, Methylphenidate, Middle Aged, Obsessive-Compulsive Disorder, Personality Assessment, Psychometrics, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
